Pharmacogenetic determinants of calcineurin inhibitor associated nephrotoxicity in liver transplant patients
Yeung, Catherine K.
MetadataShow full item record
The use of calcineurin inhibitors (tacrolimus and cyclosporine) has become standard of care in post-transplant immunosuppression. While these medications have greatly reduced organ rejection, they can cause nephrotoxicity and renal failure in some patients. A possible risk factor for this toxicity may be pharmacogenetic variability in the enzymes involved in the clearance of the calcineurin inhibitors. We conducted a prospective study in liver transplant patients at the University of Washington to evaluate whether or not variation in the genes encoding CYP3A5 (*1 vs *3) and P-glycoprotein (MDR2677, MDR3435, or MDR1236) were associated with a decline in kidney function (assessed by the estimated glomerular filtration rate) in liver transplant patients using continuous calcineurin inhibitor therapy. This study did not find a significant association between the inheritance of the CYP3A5 *1 or *3 alleles, or MDR2677, MDR3435, or MDR1236 alleles and the rate of decline of estimated glomerular filtration rate in post-liver transplant patients.
- Epidemiology